NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, News & Analysis

$0.45
0.00 (0.00 %)
(As of 08/23/2019 10:37 AM ET)
Today's Range
$0.45
Now: $0.45
$0.45
50-Day Range
$0.44
MA: $0.66
$1.28
52-Week Range
$0.43
Now: $0.45
$12.00
Volume830 shs
Average Volume792,368 shs
Market Capitalization$6.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.54
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.83 per share

Profitability

Net Income$-26,090,000.00

Miscellaneous

Employees12
Market Cap$6.91 million
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable

Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter.


Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split before market open on Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) posted its quarterly earnings results on Monday, August, 12th. The company reported ($0.95) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.96) by $0.01. View Tonix Pharmaceuticals' Earnings History.

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Tonix Pharmaceuticals.

What price target have analysts set for TNXP?

1 equities research analysts have issued 1-year price objectives for Tonix Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 788.9% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

What is the consensus analysts' recommendation for Tonix Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

Has Tonix Pharmaceuticals been receiving favorable news coverage?

News coverage about TNXP stock has trended positive this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Tonix Pharmaceuticals.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 471,300 shares, a decline of 45.5% from the June 30th total of 864,500 shares. Based on an average daily trading volume, of 555,700 shares, the days-to-cover ratio is presently 0.8 days. Approximately 20.3% of the shares of the stock are short sold. View Tonix Pharmaceuticals' Current Options Chain.

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Novavax (NVAX), SCYNEXIS (SCYX), Synthetic Biologics (SYN), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Nektar Therapeutics (NKTR) and Rigel Pharmaceuticals (RIGL).

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the folowing people:
  • Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 61)
  • Mr. Bradley Saenger, CFO & Treasurer (Age 45)
  • Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 53)
  • Mrs. Jessica Edgar Morris, Chief Operating Officer
  • Dr. Ronald R. Notvest Ph.D., MBA, Exec. VP of Commercial Planning and Devel.

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.55%), Acadian Asset Management LLC (0.43%) and A.R.T. Advisors LLC (0.20%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

Which major investors are buying Tonix Pharmaceuticals stock?

TNXP stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Acadian Asset Management LLC and A.R.T. Advisors LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.45.

How big of a company is Tonix Pharmaceuticals?

Tonix Pharmaceuticals has a market capitalization of $6.91 million. The company earns $-26,090,000.00 in net income (profit) each year or ($26.81) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]


MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  450
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel